Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for F11R/CD321 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | F11R ECD-Fc / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View F11R Products |
| Gene Delivery | F11R Promise-ORF / Lentivirus Full-length ORF for stable cell lines. |
View F11R Products |
| Benchmark Ab | Anti-F11R (Sequence of U3-1533) Recombinant positive control. |
View F11R Products |
| Validator | F11R siRNA Set For knockdown verification. |
View F11R Products |
| Related Target A | CD9 Tetraspanin interaction partner in cell migration. |
View CD9 Products |
| Related Target B | ITGB3 Integrin signaling pathway synergy in angiogenesis. |
View ITGB3 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cross-species cyno/mouse eval | Human/Mouse/Cyno ortholog proteins available with >95% purity |
| Tight Junction Conformation | HEK293 Expressed (Native Glycosylation) ECD-Fc preserving dimerization |
| Lack of Controls | Clinical Benchmark Antibodies included |
| False Positives | Validated siRNA included for specificity checks |
Live F11R/CD321 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for F11R (JAM-A) therapeutics is rooted in its overexpression in multiple malignancies, including multiple myeloma and breast cancer. Major early clinical validation has been established by monoclonal antibodies such as Daiichi Sankyo's U3-1533. As first-generation naked mAbs provide proof-of-concept for safety and targeting, the next wave of preclinical R&D is heavily exploring Antibody-Drug Conjugates (ADCs) to leverage F11R's internalization potential upon antibody binding.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibodies | Daiichi Sankyo (U3-1533) | Solid Tumors | High-affinity ECD-Fc binding assays |
| Preclinical ADCs | Academic / Biotech | Multiple Myeloma / Breast Cancer | Internalization Assays (Need HEK293 expressed antigen) |
| Cell Therapy (CAR-T) | Early Exploratory | Hematological Malignancies | Cell line construction (Lentivirus) |